EMERYVILLE, Calif.,
April 9, 2021 /PRNewswire/
-- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic
biotechnology company active in the Clean Health and Beauty markets
through its consumer brands and a top supplier of sustainable and
natural ingredients, today announced the pricing of an underwritten
public offering of an aggregate of 19,047,619 shares of its common
stock at a public offering price of $15.75 per share, which consists of a secondary
offering of 11,390,797 shares to be sold, in the aggregate, by DSM
International B.V. and affiliates of Vivo Capital LLC (the selling
stockholders) and 7,656,822 shares to be sold by Amyris.
Amyris will not receive any proceeds from the sale of shares in
the secondary offering by the selling stockholders. The gross
proceeds from the offering to Amyris, before deducting the
underwriting discount and commissions and estimated offering
expenses, and assuming no exercise of the underwriters' option to
purchase additional shares, are expected to be approximately
$120.6 million.
The selling stockholders and Amyris have granted the
underwriters a 30-day option to purchase up to an additional
2,857,142 shares of Amyris common stock at the public offering
price, less underwriting discounts and commissions. Of this 30-day
option, up to 1,708,619 shares may be sold by the selling
stockholders and up to 1,148,523 shares may be sold by Amyris. The
offering is expected to close on or about April 13, 2021, subject to the satisfaction of
customary closing conditions.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting
as the joint bookrunning managers for the offering.
The public offering is being made pursuant to an automatic shelf
registration statement on Form S-3 that was filed by Amyris with
the U.S. Securities and Exchange Commission (the "SEC") on
April 7, 2021, and automatically
became effective upon filing. The offering was made only by means
of a preliminary prospectus supplement and an accompanying
prospectus relating to the offering which have been filed with the
SEC and are available on the SEC's website at www.sec.gov. A final
prospectus supplement will be filed with the SEC, a copy of which
may be obtained, when available, from J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone
at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or
Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833)
297-2926, or by email at PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the
research, development and production of sustainable ingredients for
the Clean Health & Beauty and Flavors & Fragrances markets.
Amyris uses an impressive array of exclusive technologies,
including state-of-the-art machine learning, robotics and
artificial intelligence. Our ingredients are included in over 3,000
products from the world's top brands, reaching more than 200
million consumers. Amyris is proud to own three consumer brands -
all built around its No Compromise® promise of clean ingredients:
Biossance® clean beauty skincare, Pipette® clean baby skincare and
Purecane™, a zero-calorie sweetener naturally derived from
sugarcane. Amyris, the Amyris logo, No Compromise, Biossance,
Pipette, and Purecane are trademarks or registered trademarks of
Amyris, Inc. in the U.S. and/or other countries.
Use of forward-looking statements
This press release contains "forward-looking statements" within
the meaning of, and made pursuant to the Securities Act of 1933, as
amended, the Securities Exchange Act of 1934, as amended, and safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
expected proceeds to be received by Amyris and the timing of the
closing of the offering. These forward-looking statements may be
accompanied by such words as "aim," "anticipate," "believe,"
"could," "estimate," "expect," "forecast," "goal," "intend," "may,"
"might," "plan," "potential," "possible," "will," "would," and
other words and terms of similar meaning. These statements involve
risks and uncertainties that could cause actual results to differ
materially from those reflected our public filings, including
without limitation, risks which are outside of our full control;
risks associated with current and potential delays, work stoppages,
or supply chain disruptions caused by the coronavirus pandemic; and
the other risks and uncertainties that are described in the Risk
Factors section in our Annual Report on Form 10-K filed with the
SEC on March 5, 2021, and other
reports as filed with the SEC, the preliminary prospectus
supplement and accompanying prospectus related to the public
offering and subsequent filings with the SEC. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amyris-announces-pricing-of-a-300-0-million-public-offering-secondary-and-primary-of-common-stock-301265604.html
SOURCE Amyris, Inc.